NASDAQ:AUGX • US05105P1075
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for AUGMEDIX INC (AUGX).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2024-07-22 | Lake Street | Downgrade | Buy -> Hold |
| 2024-05-14 | Lake Street | Maintains | Buy -> Buy |
| 2024-05-14 | Maxim Group | Downgrade | Buy -> Hold |
| 2024-04-09 | Evercore ISI Group | Upgrade | In-Line -> Outperform |
| 2024-04-03 | B. Riley Securities | Reiterate | Buy |
| 2024-03-19 | Evercore ISI Group | Maintains | In-Line -> In-Line |
| 2024-03-19 | Maxim Group | Maintains | Buy -> Buy |
| 2023-12-15 | Evercore ISI Group | Initiate | In-Line |
| 2023-05-16 | Benchmark | Reiterate | Buy -> Buy |
| 2023-05-15 | B. Riley Securities | Maintains | Buy -> Buy |
| 2023-04-21 | Benchmark | Maintains | Buy |
| 2023-04-21 | Maxim Group | Maintains | Buy |
| 2023-04-20 | B. Riley Securities | Reiterate | Buy |
| 2023-03-31 | Benchmark | Reiterate | Buy |
| 2023-03-28 | Maxim Group | Maintains | Buy |
| 2022-03-07 | Lake Street | Initiate | Buy |
| 2022-01-21 | Maxim Group | Initiate | Buy |
| 2021-11-01 | William Blair | Initiate | Outperform |
| 2021-11-01 | Benchmark | Initiate | Buy |
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | ||
|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 22.17M 34.53% | 30.93M 39.51% | 44.855M 45.02% | 54.162M 20.75% | 68.554M 26.57% | 63.24M -7.75% | |
| EBITDA YoY % growth | -16.86M -31.51% | -21.51M -27.58% | -17.681M 17.80% | -22.348M -26.40% | -17.986M 19.52% | -12.852M 28.54% | |
| EBIT YoY % growth | -17.55M -28.20% | -22.37M -27.46% | -18.779M 16.05% | -27.365M -45.72% | -22.918M 16.25% | 2.04M 108.90% | |
| Operating Margin | -79.16% | -72.32% | -41.87% | -50.52% | -33.43% | 3.23% | |
| EPS YoY % growth | N/A | N/A -5.15% | -0.45 31.78% | -0.54 -20.13% | -0.48 10.38% | -0.36 26.32% |
All data in USD
| Q3 / 24 | Q4 / 24 | Q1 / 25 | Q2 / 25 | Q3 / 25 | Q4 / 25 | |
|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.14 -39.40% | -0.12 -36.00% | -0.12 -2.00% | -0.10 25.46% | -0.09 37.81% | -0.07 41.67% |
| Revenue Q2Q % growth | 13.222M 12.37% | 17.639M 39.11% | 18.886M 40.20% | 20.3M 48.57% | 21.989M 66.31% | 24.674M 39.88% |
| EBITDA Q2Q % growth | -5.794M -60.49% | -5.131M -57.87% | -4.439M 25.56% | -3.679M 53.25% | -3.132M 45.94% | -2.809M 45.26% |
| EBIT Q2Q % growth | -6.796M -54.45% | -5.91M -35.94% | -5.58M 12.83% | -4.544M 47.92% | -3.774M 44.47% | -3.339M 43.50% |
All data in USD
10 analysts have analysed AUGX and the average price target is 3.6 USD. This implies a price increase of 53% is expected in the next year compared to the current price of 2.35.
AUGMEDIX INC (AUGX) will report earnings on 2024-11-04, before the market open.
The consensus EPS estimate for the next earnings of AUGMEDIX INC (AUGX) is -0.14 USD and the consensus revenue estimate is 13.22M USD.
The number of analysts covering AUGMEDIX INC (AUGX) is 10.